Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights
Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022 NDA submission
Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022 NDA submission